Observational studyEuropean journal of pediatrics2026

Cost-benefit analysis of nirsevimab for respiratory syncytial virus prevention in infants: a population-based study.

Marcos Alonso-García et al.PubMed ↗Publisher ↗

No numbers read from the abstract.